ABSTRACT
Background Despite the availability of effective vaccines against coronavirus disease 2019 (Covid-19), the emergence of variant strains and breakthrough infections pose a challenging new reality. Booster vaccinations are needed to maintain vaccine-induced protection.
Methods ENSEMBLE2 is an ongoing, randomized, double-blind, placebo-controlled, phase 3 pivotal trial including crossover vaccination after emergency authorization of Covid-19 vaccines. Adults aged ≥18 years were randomized to receive Ad26.COV2.S or placebo as a primary dose plus a booster dose at two months. The primary endpoint was vaccine efficacy against the first occurrence of molecularly-confirmed moderate to severe–critical Covid-19 with onset ≥14 days after booster vaccination in the per-protocol population. Key efficacy, safety, and immunogenicity endpoints were also assessed.
Results The double-blind phase enrolled 31,300 participants, 14,492 of whom received 2 doses and were evaluable for efficacy (per-protocol set, Ad26.COV2.S n=7484; placebo n=7008). Baseline demographics and characteristics were balanced. Vaccine efficacy was 75.2% (adjusted 95% CI, 54.6-87.3) against moderate to severe–critical Covid-19 and was similar against symptomatic infection (75.6% [55.5-99.9]). Efficacy was consistent across participants with and without comorbidities, and reached 93.7% (58.5-99.9) in the US. Vaccine efficacy against severe–critical Covid-19 was 100% (32.6-100.0; 0 vs 8 cases). The booster vaccine induced robust humoral responses and exhibited an acceptable safety profile.
Conclusions A homologous Ad26.COV2.S booster administered 2 months after primary single-dose vaccination in adults led to high vaccine efficacy, including against any symptomatic infection and SARS-CoV-2 variants prevalent during the study. (Funding: Janssen Research and Development and others; ENSEMBLE2 ClinicalTrials.gov number, NCT04614948.)
Competing Interest Statement
KH, AV, JS, MLG, JV, TK, GS, HS, JVH, MD, and FS are employees of Johnson & Johnson and hold Johnson & Johnson stock/stock options. CT, DL, and IVD are employees of Johnson & Johnson. JRG is an employee of Johnson & Johnson and holds Johnson & Johnson stock/stock options; he is a former employee of GSK, holds GSK stock/stock options, and has received funding grants from GSK Vaccines. CS has received funding grants for research from Janssen-Cilag, AbbVie, Apeiron, B.Braun, Cepheid, Eli Lilly, GSK, Corat Therapeutics, Gilead, MSD, Roche, and ViiV Healthcare; received consulting fees from AbbVie, Cepheid, Formycon, Gilead, GSK, Molecular partners, MSD, Swedish Orphan Biovitrium, Roche, and ViiV Healthcare; received honoraria from AbbVie, Cepheid, Formycon, Gilead, GSK, Gilead, Molecular partners, MSD, Swedish Orphan Biovitrium, Roche, and ViiV Healthcare; received travel support from AbbVie, Cepheid, Formycon, Gilead, GSK, Gilead, Molecular partners, MSD, Swedish Orphan Biovitrium, Roche, and ViiV Healthcare. SF has received research grants to his institution from Janssen/Johnson & Johnson, Pfizer, Sanofi, GSK, Merck, AstraZeneca, and Valneva (no personal fees); consulting fees from Janssen/Johnson & Johnson and GSK CureVac; fees to his institution for participation on a data safety monitoring board or advisory board from AstraZeneca, Medimmune, Sanofi, Pfizer, Seqirus, Sandoz, Merck, and Janssen/Johnson & Johnson; and was chair of two UK NICE sessions (expenses paid per NICE financial regulations).
Clinical Trial
NCT04614948
Funding Statement
This work was supported by Janssen Vaccines & Prevention B.V. in collaboration with the Biomedical Advanced Research and Development Authority, the Department of Defense, the National Institutes of Health, and the COVID-19 Prevention Network. This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), under Other Transaction Agreement HHSO100201700018C and from the National Institute of Allergy and Infectious Diseases (NIAID), NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been followed, all necessary institutional review board (IRB) and/or ethics committee approvals have been obtained, all necessary patient/participant consent has been obtained, and the appropriate institutional forms archived. The COV3009 (ENSEMBLE2) study was reviewed and approved by local ethics committees and IRBs (Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium; Comissao Nacional de Etica em Pesquisa, Brasilia, Brazil; Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia), Bogota, Colombia; Comite de Protection des Personnes Ile de France III, Paris, France; Ethik-Kommission der Fakultaet f. Medizin der Technischen Universitaet Muenchen, Muenchen, Germany; Single Joint Research Ethics Board, Manila City, Philippines; Pharma Ethics, Pretoria, South Africa; Hospital Universitario La Paz, Madrid, Spain; UK NHS Research Ethics Service, Health Research Authority, London, United Kingdom; Copernicus Group IRB, Cary, North Carolina, United States.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.
